title: Hearing loss in congenital diaphragmatic hernia (CDH) survivors: is it as prevalent as we think?
abstract: OBJECTIVE
  The incidence of sensorineural hearing loss (SNHL;>20 dB loss) in CDH survivors is debated. We evaluated long-term audiological outcomes at a single tertiary care center with ECMO capability and an established neonatal follow-up program.
  
  
  METHODS
  With REB approval, records of CDH survivors from 2000 to 2010 were retrospectively analyzed. Demographic, postnatal, and audiometric information was gathered. All underwent auditory brainstem response (ABR) or otoacoustic emissions screening before discharge and complete audiological surveillance. Thirty-three patients were evaluated to age 4+ years with others continuing follow-up.
  
  
  RESULTS
  Forty-three patient records were reviewed with 1 excluded (transferred to another institution). Median GA and BW were 39 weeks (35-41) and 3.1 kg (2-4), respectively. Median ventilation days were 10 (2-189) with 34 infants ventilated 5+ days. Sixteen (36%) received HFOV, 21 (49%) iNO, and 5 (12%) ECMO. The median time to CDH repair was 3 days (1-23), and 11 (26%) required patch repair. Nine infants (21%) received diuretics and oxygen after discharge. Audiological surveillance identified only one patient with SNHL (received HFO, iNO, and patch repair).
  
  
  CONCLUSIONS
  Neonatal screening identifies CDH survivors at risk for hearing difficulties but must be followed with comprehensive testing until school age. The incidence of SNHL may be less than previously reported in this population.
authors.affiliation: Division of Pediatric General Surgery, The Montreal Children's Hospital, Montreal, QC, Canada H3H 1P3.
authors.forename: Marnie Goodwin
authors.initials: MG
authors.lastname: Wilson
authors.forename: Patricia
authors.initials: P
authors.lastname: Riley
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Hurteau
authors.forename: Robert
authors.initials: R
authors.lastname: Baird
authors.forename: Pramod S
authors.initials: PS
authors.lastname: Puligandla
mesh_terms: D000015:Abnormalities, Multiple; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D001299:Audiometry; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use; D042241:Early Diagnosis; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D006548:Hernia, Diaphragmatic / Q000150:complications / Q000601:surgery / Q000628:therapy; D065630:Hernias, Diaphragmatic, Congenital; D059685:Herniorrhaphy; D006612:High-Frequency Ventilation / Q000009:adverse effects / Q000706:statistics & numerical data; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D015997:Neonatal Screening; D009466:Neuromuscular Blocking Agents / Q000009:adverse effects; D009569:Nitric Oxide / Q000627:therapeutic use; D009864:Ontario / Q000453:epidemiology; D010102:Oxygen Inhalation Therapy; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D015995:Prevalence; D012307:Risk Factors; D017741:Survivors
chemical_list: D000900:Anti-Bacterial Agents; D004232:Diuretics; D009466:Neuromuscular Blocking Agents; D009569:Nitric Oxide